Lymphocytic Leukemia, Chronic Clinical Trial
Official title:
A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare The Efficacy and Safety of A Combined Regimen of Obinutuzumab and Venetoclax Versus Obinutuzumab and Chlorambucil in Previously Untreated Patients With CLL and Coexisting Medical Conditions
Verified date | June 2024 |
Source | Hoffmann-La Roche |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This open-label, multicenter, randomized Phase III study is designed to compare the efficacy and safety of a combined regimen of obinutuzumab and venetoclax versus obinutuzumab + chlorambucil in participants with chronic lymphocytic leukemia (CLL) and coexisting medical conditions. The time on study treatment was approximately one year and the follow-up period will be up to 9 years.
Status | Active, not recruiting |
Enrollment | 445 |
Est. completion date | August 31, 2025 |
Est. primary completion date | August 17, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Documented previously untreated CLL according to the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria - CLL requiring treatment according to IWCLL criteria - Total Cumulative Illness Rating Scale (CIRS score) greater than (>) 6 - Adequate marrow function independent of growth factor or transfusion support within 2 weeks of screening as per protocol, unless cytopenia is due to marrow involvement of CLL - Adequate liver function - Life expectancy > 6 months - Agreement to use highly effective contraceptive methods per protocol Exclusion Criteria: - Transformation of CLL to aggressive Non-Hodgkin's lymphoma (Richter's transformation or pro-lymphocytic leukemia) - Known central nervous system involvement - Participants with a history of confirmed progressive multifocal leukoencephalopathy (PML) - An individual organ/ system impairment score of 4 as assessed by the CIRS definition limiting the ability to receive the treatment regimen of this trial with the exception of eyes, ears, nose, throat organ system - Participants with uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia - Inadequate renal function - History of prior malignancy, except for conditions as listed in the protocol if participants have recovered from the acute side effects incurred as a result of previous therapy - Use of investigational agents or concurrent anti-cancer treatment within the last 4 weeks of registration - Participants with active bacterial, viral, or fungal infection requiring systemic treatment within the last two months prior to registration - History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products - Hypersensitivity to chlorambucil, obinutuzumab, or venetoclax or to any of the excipients - Pregnant women and nursing mothers - Positive test results for chronic hepatitis B virus (HBV) infection (defined as positive hepatitis B surface antigen [HBsAg] serology) or positive test result for hepatitis C (hepatitis C virus [HCV] antibody serology testing) - Participants with known infection with human immunodeficiency virus (HIV) or human T-cell leukemia virus-1 (HTLV-1) - Requires the use of warfarin, marcumar, or phenprocoumon - Received agents known to be strong and moderate Cytochrome P450 3A inhibitors or inducers within 7 days prior to the first dose of study drug |
Country | Name | City | State |
---|---|---|---|
Argentina | Hospital Italiano | Buenos Aires | |
Australia | Royal Adelaide Hospital; Haematology Clinical Trials | Adelaide | South Australia |
Australia | Ashford Cancer Centre Research; Internal Medicine/Medical Oncology | Ashford | South Australia |
Australia | Box Hill Hospital | Box Hill | Victoria |
Australia | The Townsville Hospital | Douglas | Queensland |
Australia | The Northern Hospital | Epping | Victoria |
Australia | Liverpool Hospital | Liverpool | New South Wales |
Australia | Monash Medical Centre; Haematology | Melbourne | Victoria |
Australia | Tweed Hospital | Tweed Heads | New South Wales |
Australia | Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology | Woolloongabba | Queensland |
Austria | Tiroler Landeskrankenanstalten Ges.M.B.H.; Innere Medizin Abt. Für Hämatologie & Onkologie | Innsbruck | |
Austria | Hanusch-Krankenhaus; Iii. Medizinische Abt. | Wien | |
Austria | Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Hämatologie & Hämostaseologie | Wien | |
Austria | Wilhelminenspital; I. Medizinische Abt. | Wien | |
Brazil | Hospital das Clinicas - UFRGS | Porto Alegre | RS |
Brazil | Hospital das Clinicas - FMUSP | Sao Paulo | SP |
Brazil | Hospital Santa Marcelina | Sao Paulo | SP |
Brazil | Hospital Sírio-Libanês | Sao Paulo | SP |
Brazil | Instituto de Ensino e Pesquisa Sao Lucas - IEP | Sao Paulo | SP |
Bulgaria | UMHAT Dr Georgi Stranski; Hematology | Pleven | |
Bulgaria | UMHAT " Sveti Georgi" Plovdiv - Clinic of Oncology and Hematology | Plovdiv | |
Bulgaria | University Hospital Sv.Georgi Clnic of Hematology; Hematology | Plovdiv | |
Bulgaria | University Multiprofile Hospital For Active Treatment "Sveti Ivan Rilski" EAD; clinical hematology | Sofia | |
Bulgaria | MHAT Hristo Botev; First Internal Department | Vratsa | |
Canada | Tom Baker Cancer Centre; Dept of Medicine | Calgary | Alberta |
Canada | Queen Elizabeth II Health Sciences Centre; Oncology | Halifax | Nova Scotia |
Canada | Jewish General Hospital | Montreal | Quebec |
Croatia | University Hospital Center Zagreb; Haematology Department | Zagreb | |
Croatia | University Hospital Merkur Clinic for Internal Medicine/ Hematology | Zagreb | |
Denmark | Herlev Hospital | Herlev | |
Denmark | Rigshospitalet | København Ø | |
Denmark | Sjaellands Universitetshospital, Roskilde | Roskilde | |
Denmark | Sygehus Lillebælt, Vejle | Vejle | |
Estonia | North Estonia medical Centre; Hematology | Tallinn | |
Estonia | Tartu Uni Hospital; Hematology - Oncology Clinic | Tartu | |
France | CHU Besançon - Hôpital Jean Minjoz | Besançon Cedex | |
France | Institut d'Hématologie de Basse Normandie | Caen | |
France | Chu Estaing; Hematologie Clinique Adultes | Clermont Ferrand | |
France | Hopital Henri Mondor | Creteil | |
France | CHU de Dijon - Hopital le Bocage | Dijon | |
France | CHU de Grenoble | Grenoble | |
France | Centre Jean Bernard | Le Mans | |
France | Centre Leon Berard; Departement Oncologie Medicale | Lyon | |
France | Hôpital Saint Eloi; Service d?Hématologie et Oncologie Clinique - Recherche Clinique | Montpellier | |
France | Hopital Hotel Dieu Et Hme;Hopital De Jour | Nantes | |
France | Hopital Saint Louis ; Service d Oncologie Medicale Fougere 6 (Pr Misset) | Paris | |
France | Hopital Pontchaillou; Hematologie Clinique | Rennes | |
France | Centre Henri Becquerel; Hematologie | Rouen | |
France | CH de Toulon Hôpital Sainte Musse | Toulon | |
France | Institut Gustave Roussy - Hematologie | Villejuif | |
Germany | Uniklinik RWTH Aachen; Klinik IV; Klinik Hämatologie, Onkologie, Hämostaseologie und Stamm. | Aachen | |
Germany | Gesundheitszentrum St. Marien GmbH; Med. II, Hämatologie/Onkologie | Amberg | |
Germany | Charite - Campus Virchow-Klinikum | Berlin | |
Germany | Charite - Universitätsmedizin Berlin | Berlin | |
Germany | BAG Freiberg-Richter, Jacobasch, Illmer, Wolf; Gemeinschaftspraxis Hämatologie-Onkologie | Dresden | |
Germany | Uniklinikum "Carl Gustav Carus"; Med. Klinik 1; Hämatologie, Zelltherapie und Medizinische Onkologie | Dresden | |
Germany | Universitätsklinikum Essen; Klinik für Hämatologie | Essen | |
Germany | Klinik Esslingen; Klinik für Allgemeine Innere Medizin, Onkologie/Haematologie | Esslingen | |
Germany | Klinikum Frankfurt/Oder | Frankfurt/Oder | |
Germany | Uniklinikum Freiburg | Freiburg | |
Germany | Uni Göttingen, Georg-August-Universität; Klinik für Hämatologie und Medizinische Onkologie | Göttingen | |
Germany | Universitaetsklinikum Heidelberg | Heidelberg | |
Germany | Stiftung Kathol. Krankenhaus Marienhospital Herne Klinik Mitte | Herne | |
Germany | Praxisklinik für Hämatologie und Onkologie Koblenz | Koblenz | |
Germany | Universitätsklinikum Köln; Innere Medizin I; Onkologie, Hämatologie | Köln | |
Germany | Tagesklinik Landshut; Hämatologie/Onkologie | Landshut | |
Germany | Kliniken Maria Hilf GmbH Innere Medizin I | Mönchengladbach | |
Germany | Klinikum rechts der Isar der Technischen Universität München | Munchen | |
Germany | Klinikum der Universität München, Campus Großhadern; Medizinische Klinik und Poliklinik III | München | |
Germany | München Klinik Schwabing; Klinik für Hämatologie, Onkologie, Immunologie | München | |
Germany | Klinikum Schwäbisch Gmünd | Mutlangen | |
Germany | Gemeinschaftspraxis Dr. med. Holger Klaproth | Neunkirchen/Saar | |
Germany | Brüderkrankenhaus St. Josef Paderborn | Paderborn | |
Germany | Krankenhaus Barmherzige Bruder Regensburg | Regensburg | |
Germany | Marienhospital | Stuttgart | |
Germany | Robert-Bosch-Krankenhaus | Stuttgart | |
Germany | Universitätsklinikum Tübingen | Tübingen | |
Germany | Universtitätsklinikum Ulm; Klinik für Innere Medizin III | Ulm | |
Germany | Medizinisches Versorgungszentrum Nuklearmedizin-Strahlentherapie-Onkologie | Weiden | |
Italy | Arcispedale S. Anna; Sezione Di Ematologia | Ferrara | Emilia-Romagna |
Italy | Ospedali Riuniti Papardo-Piemonte; Struttura Complessa Di Ematologia | Messina | Lazio |
Italy | Ospedale San Raffaele | Milano | Lombardia |
Italy | Uni Cattolica; Divisione Di Ematologia | Roma | Lazio |
Italy | Az. Osp. S. Maria; Dept. Di Oncologia Medica | Terni | Umbria |
Italy | AOU Città della Salute e della Scienza di Torino - Presidio Le Molinette | Torino | Lazio |
Italy | Ospedale dell' Angelo; U.O. Ematologia | Venezia Mestre | Veneto |
Mexico | Hospital General de Culiacan | Culiacan | Sinaloa |
New Zealand | Canterbury Health Laboratories; Haematology | Christchurch | |
New Zealand | Dunedin Hospital | Dunedin | |
New Zealand | Midcentral District Health Board | Palmerston North | |
New Zealand | Wellington Hospital | Wellington | |
Poland | Uniwersytecki Szpital Kliniczny w Bia?ymstoku, Klinika Hematologii z Pododdzia?em Chorob Naczyn | Bialystok | |
Poland | Samodzielny Public Zaklad | Chorzów | |
Poland | Wojewódzki Szpital Specjalistyczny im.Miko?ajaKopernika;KlinikaHematologiiUniwersytetuMedycznego | Lodz | |
Poland | Wojewodzki Szpital Specjalistyczny im. J. Korczaka; Oddzia? Chorób Wewnetrznych/Hematologiczny | Slupsk | |
Poland | Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wroc?awiu; Klinika Hematologii | Wroclaw | |
Romania | Fundeni Clinical Inst. ; Hematology Dept | Bucharest | |
Romania | Institutul Regional de Oncologie Iasi; Clinica de Hematologie | Iasi | |
Romania | Spitalul Clinic Judetean de Urgenta Targu-Mures; compartiment Hematologie | Targu-mures | |
Russian Federation | Republican Clinical Oncologic Dispensary of Republic Of Tatarstan | Kazan | Tatarstan |
Russian Federation | Moscow State Budgetary Healthcare Institution | Moscow | Moskovskaja Oblast |
Russian Federation | Regional Clinical Hospital N.A. Semashko; Hematology | Nizhny Novgorod | Niznij Novgorod |
Russian Federation | Penza Regional Oncology Dispensary | Penza | |
Russian Federation | Clinical MSCh No1 | Perm | |
Russian Federation | Rostov State Medical Uni ; Hematology | Rostov-na-donu | Rostov |
Russian Federation | SBEI of HPE ?Bashkir State Medical University? of MoH RF | UFA | Baskortostan |
Spain | Hospital Clínic i Provincial; Servicio de Hematología y Oncología | Barcelona | |
Spain | Hospital del Mar; Servicio de Hematologia | Barcelona | |
Spain | Hospital Universitari Vall d'Hebron; Servicio de Hematologia | Barcelona | |
Spain | Hospital Universitario de Canarias;servicio de Hematologia | La Laguna | Tenerife |
Spain | Hospital Univ. 12 de Octubre; Servicio de Hematologia | Madrid | |
Spain | Hospital Universitario de la Princesa; Servicio de Hematologia | Madrid | |
Spain | Hospital Universitario La Paz | Madrid | |
Spain | Hospital Universitario Ramón y Cajal | Madrid | |
Spain | Complejo Hospitalario de Navarra | Pamplona | Navarra |
Spain | Hospital Clinico Universitario de Salamanca;Servicio de Hematologia | Salamanca | |
Spain | Hospital Universitario Virgen del Rocio | Sevilla | |
Spain | Complejo Hospitalario de Toledo- H. Virgen de la Salud; Servicio de Hematología | Toledo | |
Spain | Hospital Arnau de Vilanova (Valencia) Servicio de Hematologia | Valencia | |
Spain | Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia | Valencia | |
Switzerland | Inselspital Bern; Hämatologie und Hämatologisches Zentrallabor | Bern | |
Switzerland | Luzerner Kantonsspital, Hämatologie | Luzern | |
Switzerland | Universitätsspital Zürich Medizin Hämatologie; Klinik für Hämatologie | Zürich | |
United Kingdom | Birmingham Heartlands Hospital | Birmingham | |
United Kingdom | Boston Pilgrim Hospital | Boston,Lincolnshire | |
United Kingdom | Western General Hospital; Department of Haematology | Edinburgh | |
United Kingdom | Lincoln County Hospital | Lincoln | |
United Kingdom | University Hospital Southampton NHS Foundation Trust | Southhampton | |
United States | Winship Cancer Institute | Atlanta | Georgia |
United States | Henry Ford Hospital | Detroit | Michigan |
United States | City of Hope | Duarte | California |
United States | San Diego Pacific Hematology Assocates | Encinitas | California |
United States | Banner MD Anderson Cancer Center | Gilbert | Arizona |
United States | Ingalls Memorial Hospital | Harvey | Illinois |
United States | UC San Diego Health System | La Jolla | California |
United States | Joe Arrington Cancer Center | Lubbock | Texas |
United States | Moffitt Cancer Center | Tampa | Florida |
Lead Sponsor | Collaborator |
---|---|
Hoffmann-La Roche | AbbVie, German CLL Study Group |
United States, Argentina, Australia, Austria, Brazil, Bulgaria, Canada, Croatia, Denmark, Estonia, France, Germany, Italy, Mexico, New Zealand, Poland, Romania, Russian Federation, Spain, Switzerland, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression Free Survival (PFS) Based on Investigator Assessment According to IWCLL Criteria | PFS was determined according to IWCLL 2008 criteria and defined as the time from randomization to the first occurrence of PD or death from any cause. Disease progression was characterized by at least one of the following: 1) >/= 50% increase in the absolute number of circulating lymphocytes to at least 5*10^9/L, 2) Appearance of new palpable lymph nodes (> 15 mm in longest diameter) or any new extra-nodal lesion; 3) >/= 50% increase in the longest diameter of any previous site of lymphadenopathy; 4) >/= 50% increase in the enlargement of the liver and/or spleen; 5) Transformation to a more aggressive histology. | Baseline until disease progression or death up to approximately 3.75 years | |
Secondary | Progression Free Survival (PFS) Based on Institutional Review Committee (IRC)-Assessments According to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) Criteria | PFS was determined according to IWCLL 2008 criteria and defined as the time from randomization to the first occurrence of progressive disease (PD) or death from any cause. Disease progression was characterized by at least one of the following: 1) >/= 50% increase in the absolute number of circulating lymphocytes to at least 5*10^9/L, 2) Appearance of new palpable lymph nodes (> 15 mm in longest diameter) or any new extra-nodal lesion; 3) >/= 50% increase in the longest diameter of any previous site of lymphadenopathy; 4) >/= 50% increase in the enlargement of the liver and/or spleen; 5) Transformation to a more aggressive histology. | Baseline until disease progression or death up to approximately 3.75 years | |
Secondary | Percentage of Participants With an Overall Response (OR) at Completion of Treatment, as Determined by the Investigator According to IWCLL Criteria | OR was defined as complete response (CR), CR with incomplete bone marrow recovery (CRi), or partial response (PR) according to IWCLL 2008 criteria. CR requires all of the following: peripheral blood lymphocytes below 4x10^9/L, absence of lymphadenopathy by physical examination and computed tomography (CT) scan, no hepatomegaly or splenomegaly, absence of disease or constitutional symptoms, blood counts of neutrophils >1.5*10^9/L, platelets >100*10^9/L and hemoglobin >110 g/L, bone marrow at least normocellular for age without clonal infiltrate (except for Cri). PR: two of the following features for at least 2 months: >/= 50% decrease in peripheral blood lymphocyte count from the pretreatment value, >/=50% reduction in lymphadenopathy, >/=50% reduction of liver and/or spleen enlargement, and at least one of the following blood counts: neutrophils >1.5*10^9/L, platelets >100*10^9/L and hemoglobin >110 g/L. | At the completion of treatment assessment 3 months after treatment completion (at approximately 15 months) | |
Secondary | Percentage of Participants With a Complete Response Rate (CRR) at the Completion of Treatment Assessment as Determined by the Investigator According to IWCLL Criteria | CRR was defined as the rate of a clinical response of CR or CRi according to IWCLL 2008 criteria. CR requires all of the following: peripheral blood lymphocytes below 4x10^9/L, absence of lymphadenopathy by physical examination and CT scan, no hepatomegaly or splenomegaly, absence of disease or constitutional symptoms, blood counts of neutrophils >1.5*10^9/L, platelets >100*10^9/L and hemoglobin >110 g/L, bone marrow at least normocellular for age without clonal infiltrate (except for Cri). | At the completion of treatment assessment 3 months after treatment completion (at approximately 15 months) | |
Secondary | Percentage of Participants With Minimal Residual Disease (MRD) Negativity in Peripheral Blood as Measured by Allele-Specific Oligonucleotide Polymerase Chain Reaction (ASO-PCR) at Completion of Treatment | MRD negativity was defined as having < 1 CLL cell per 10,000 leucocytes in peripheral blood. | At the completion of treatment assessment 3 months after treatment completion (at approximately 15 months) | |
Secondary | Percentage of Participants With MRD Negativity in Bone Marrow as Measured by ASO-PCR at Completion of Treatment | MRD negativity was defined as having < 1 CLL cell per 10,000 leucocytes in bone marrow. | At the completion of treatment assessment 3 months after treatment completion (at approximately 15 months) | |
Secondary | Overall Survival (OS) | OS was defined as the time between the date of randomization and the date of death due to any cause. | Baseline until death, up to approximately 10.75 years | |
Secondary | Percentage of Participants With MRD Negativity in Peripheral Blood as Measured by ASO-PCR at Completion of Combination Treatment Assessment | MRD negativity was defined as having < 1 CLL cell per 10,000 leucocytes in peripheral blood. | Day 1 Cycle 9 or 3 months after last IV infusion, approximately 9 months | |
Secondary | Percentage of Participants With MRD Negativity in Bone Marrow as Measured by ASO-PCR at Completion of Combination Treatment Assessment | MRD negativity was defined as having < 1 CLL cell per 10,000 leucocytes in bone marrow. | Day 1 Cycle 9 or 3 months after last IV infusion at approximately 9 months | |
Secondary | Percentage of Participants With OR at Completion of Combination Treatment Response Assessment | OR was defined as CR, CRi or PR according to IWCLL 2008 criteria. CR required all of the following: peripheral blood lymphocytes below 4x10^9/L, absence of lymphadenopathy by physical examination, no hepatomegaly or splenomegaly, absence of disease or constitutional symptoms, blood counts of neutrophils >1.5*10^9/L, platelets >100*10^9/L and hemoglobin >110 g/L. PR: two of the following features for at least 2 months: >/= 50% decrease in peripheral blood lymphocyte count from the pretreatment value, >/=50% reduction in lymphadenopathy, >/=50% reduction of liver and/or spleen enlargement, and at least one of the following blood counts: neutrophils >1.5*10^9/L, platelets >100*10^9/L and hemoglobin >110 g/L. | Day 1 Cycle 7 or 28 days after last IV infusion, approximately 6 months | |
Secondary | Duration of Objective Response (DOR) | PD was defined as lymphadenopathy, >=50% increase in liver or spleen size, >=50% increase in lymphocyte count, transformation to a more aggressive histology or occurrence of cytopenia. | Time from the first occurrence of a documented objective response to the time of PD as determined by the investigator or death from any cause, up to approximately 10.75 years | |
Secondary | Percentage of Participants By Best Response Achieved (CR, CRi, PR, Stable Disease (SD), or PD) | CR: peripheral blood lymphocytes below 4x10^9/L, absence of lymphadenopathy by physical examination and CT scan, no hepatomegaly or splenomegaly, absence of disease or constitutional symptoms, blood counts of neutrophils >1.5*10^9/L, platelets >100*10^9/L and hemoglobin >110 g/L, bone marrow at least normocellular for age without clonal infiltrate (except for Cri). PR: any two for at least 2 months: >/= 50% decrease in peripheral blood lymphocyte count from the pretreatment value, >/=50% reduction in lymphadenopathy, >/=50% reduction of liver and/or spleen enlargement, and at least one of the following blood counts: neutrophils >1.5*10^9/L, platelets >100*10^9/L and hemoglobin >110 g/L. PD: lymphadenopathy, >=50% increase in liver or spleen size, >=50% increase in lymphocyte count, transformation to a more aggressive histology or occurrence of cytopenia. SD: a non-response and used to characterize participants who did not achieve a CR or a PR, and who have not exhibited PD. | Baseline up to the completion of treatment assessment 3 months after treatment completion (up to approximately 15 months) | |
Secondary | Event-Free Survival | Time between date of randomization and the date of disease progression/relapse on the basis of investigator-assessment, death, or start of a new anti-leukemic therapy, up to 10.75 years | ||
Secondary | Time to Next Anti-Leukemic Treatment | Time between the date of randomization and the date of first intake of new anti-leukemic therapy, up to 10.75 years | ||
Secondary | Number of Participants With Adverse Events (AEs) | An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. | Up to approximately 10.75 years | |
Secondary | Percentage of Participants With CD19 + /CD5+ B Cells or CD14+ Monocytes | Baseline up to approximately 10.75 years | ||
Secondary | Percentage of Participants With Human-Anti-Human Antibodies | Baseline up to approximately 10.75 years | ||
Secondary | Percentage of Participants Recorded as Premature Study Withdrawals | Up to approximately 10.75 years | ||
Secondary | Plasma Concentrations of Venetoclax | Pre-venetoclax dose (0 hour) and 4 hours post- venetoclax dose on Day 1 Cycle 4 | ||
Secondary | Serum Concentrations of Obinutuzumab | Pre-obinutuzumab infusion (0 hour) and end of obinutuzumab infusion on Day 1 Cycle 4 | ||
Secondary | Change From Baseline in M.D. Anderson Symptom Inventory-CLL (MDASI-CLL) Score | The MDASI-CLL is a questionnaire of 25 items related to CLL specific symptoms that a participant may have experienced in the past 24 hours. Participants were asked to rate the severity of 13 symptoms called mean core symptom severity (i.e., pain, fatigue, nausea, disturbed sleep, distressed, shortness of breath, remembering things, lack of appetite, drowsy, dry mouth, sadness, vomiting, and numbness or tingling), 6 disease-specific symptoms called mean module symptom severity (night sweats, fevers and chills, lymph node swelling, diarrhea, easy bruising or bleeding, and constipation) and 6 mean interference on life questions (i.e., general activity, walking, work, mood, relations with other people, and enjoyment of life) on a scale from 0 to 10 with 0 indicating that the symptom is "not present" or "did not interfere" with the participant's activities and 10 indicating "as bad as you can imagine" or "interfered completely". Scores were averaged (range 0 to 10) for each of three parts. | Baseline up to approximately 10.75 years | |
Secondary | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQC30) | The EORTC QLQ-C30 is a validated and reliable self-report measure consisting of 30 questions incorporated into five functional scales (physical, role, cognitive, emotional, and social scales), three symptom scales (fatigue, pain, nausea, and vomiting scales), and a global health status/global quality-of-life scale. The remaining single items (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea) assess the additional symptoms experienced by patients with cancer and the perceived financial burden of treatment. The 28 function and symptom items were scored on a 4-point scale that ranged from "not at all" to "very much," and the 2 global health status/global quality-of-life items were scored on a 7-point scale that ranged from "very poor" to "excellent." Raw average scale scores were linearly transformed to range 0-100 with higher scores indicating higher response levels (i.e., higher functioning, higher symptom severity). | Baseline up to approximately 10.75 years | |
Secondary | Change From Baseline in EuroQol 5 Dimension Questionnaire (EQ-5D-3L) | The EQ-5D-3L questionnaire is a generic, preference based health utility measure that assesses 5 health states (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and is used to build a composite of the patient's health status. The EQ-5D-3L was employed in this study to calculate health utilities for economic modeling, which ranged 0-1. The EQ-5D-3L also contained a visual analog scale (VAS) to assess the participant's overall health, which ranged from 0-100 with a higher score indicating a worse health status. | Baseline up to approximately 10.75 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01072240 -
An Observational Study on Infusion-related Adverse Events at Administration of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia
|
N/A | |
Completed |
NCT00754650 -
A Proof of Concept Study of the Safety, Tolerability, and Efficacy of Avastin (Bevacizumab) in Patients With Chemo-naive Chronic Lymphocytic Leukemia
|
Phase 2 | |
Active, not recruiting |
NCT02500407 -
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04704323 -
CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
|
||
Active, not recruiting |
NCT01414205 -
A Study Comparing RO5072759 (GA101) 1000 mg Versus 2000 mg in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GAGE)
|
Phase 2 | |
Completed |
NCT01224093 -
An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC)
|
N/A | |
Completed |
NCT01395615 -
An Observational Study on The Health Related Quality of Life in Patients With Chronic Lymphocytic Leukaemia
|
N/A | |
Completed |
NCT00532129 -
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia.
|
Phase 2 | |
Completed |
NCT02013817 -
CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy
|
Phase 2 | |
Completed |
NCT01685892 -
A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT00738374 -
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia.
|
Phase 2 | |
Completed |
NCT00241358 -
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT01056510 -
A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)
|
Phase 4 | |
Completed |
NCT01300247 -
A Study of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GALTON)
|
Phase 1 | |
Terminated |
NCT01271010 -
A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status
|
Phase 4 | |
Completed |
NCT00718549 -
A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)
|
Phase 3 | |
Completed |
NCT01263704 -
A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia
|
Phase 2 | |
Completed |
NCT00431873 -
A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia
|
Phase 2 | |
Completed |
NCT01178086 -
A Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)
|
||
Terminated |
NCT02292225 -
Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)
|
Phase 1 |